Can a daily pill outperform chemo for advanced pancreatic cancer?
Yes. In this phase 3 trial, the once-daily pill daraxonrasib roughly doubled how long patients lived compared with chemotherapy. People taking the drug lived a median of 13.2 months, versus 6.7 months with standard chemo.
That difference matters enormously. Pancreatic cancer is one of the hardest cancers to treat, and there have been almost no real advances in decades. This new pancreatic cancer treatment is the first RAS-targeting drug to win a positive phase 3 trial in this disease. For patients who have run out of good options, that is a genuine breakthrough.
How does this drug work?
Most pancreatic cancers are driven by a faulty protein called RAS. Think of RAS as a stuck “on” switch that tells cancer cells to keep growing. For years, scientists struggled to make a drug that could block it. Daraxonrasib is a new kind of “RAS(ON) inhibitor,” meaning it targets RAS while it is in its active, switched-on state. By shutting off that signal, the drug aims to slow or stop the cancer’s growth. The best part for patients is that it comes as a pill taken once a day, instead of an IV drip.
What the data show
The results were strong and clear. About 500 patients with previously treated metastatic pancreatic cancer took part in the study. Those who received daraxonrasib lived a median of 13.2 months, nearly double the 6.7 months seen with chemotherapy. The risk of death was cut by about 60 percent, with a hazard ratio of 0.40 and a p-value below 0.0001, which means the result is highly unlikely to be due to chance. The drug also slowed how fast the cancer grew, improving what doctors call progression-free survival.
One of the most surprising findings was who benefited. The drug helped patients whether their tumors carried a RAS mutation or not. On top of that, patients generally had fewer side effects with the pill than with chemotherapy, which is rare for a cancer drug that works this well.
Dr. Kumar’s Take
I find this trial genuinely exciting, and I do not say that often about pancreatic cancer. For most of my career, this disease has been a wall we keep running into. Doubling median survival with a once-daily pill, and with fewer side effects than chemo, is the kind of result we have been waiting decades to see. The fact that it worked across both RAS-mutant and RAS-wild-type tumors is especially intriguing and hints that we may not fully understand yet why it helps so broadly.
That said, I want to stay grounded. Median survival of 13.2 months is a major step forward, but it is not a cure. This was a trial in people who had already been treated, and we will need more time to see long-term results and how the drug performs in everyday practice. Still, this is real progress, and progress here has been painfully rare.
Who benefits most
The study focused on people with metastatic pancreatic cancer that had already been treated once. Metastatic means the cancer has spread beyond the pancreas to other parts of the body. These are patients who have typically already tried first-line chemotherapy and have very limited choices left. In that hard situation, a treatment that nearly doubles survival is a big deal. Because the benefit showed up regardless of RAS mutation status, the drug may eventually help a wider group than first expected, though more research is needed before that is certain.
Practical Takeaways
- If you or a loved one has metastatic pancreatic cancer, ask your oncologist whether RAS-targeting drugs like daraxonrasib are available, either approved or through a clinical trial.
- Remember this trial studied people whose cancer had already been treated once, so the findings apply most directly to that second-line setting.
- Keep your expectations realistic and hopeful at the same time: this drug nearly doubled survival but is not a cure, so it works best as part of an overall care plan.
Related Studies and Research
- Phase I trial of high-dose vitamin C with gemcitabine in pancreatic cancer
- High-dose intravenous vitamin C boosts chemo sensitivity in ovarian cancer
- Saccharomyces boulardii reduces side-effects in H. pylori triple therapy
- Status of oral rehydration therapy in Bangladesh: how widely is it used?
FAQs
What is daraxonrasib and how is it taken?
Daraxonrasib is a new type of cancer drug known as a RAS(ON) inhibitor. It works by blocking RAS, a faulty protein that drives the growth of most pancreatic cancers, while that protein is in its active state. Unlike chemotherapy, which is usually given through an IV, daraxonrasib is a pill taken once a day by mouth. This makes treatment far more convenient and may help explain why patients reported fewer side effects.
Does this drug only work for patients with RAS mutations?
No, and that is one of the most striking parts of the study. Daraxonrasib improved survival in patients whether or not their tumors carried a RAS mutation. This was unexpected, since the drug is designed to target RAS. It suggests the biology may be more complex than a simple on-off switch, and researchers will likely study why the benefit extended so broadly.
Is pancreatic cancer usually this hard to treat?
Yes. Pancreatic cancer has long been one of the deadliest and most stubborn cancers, with very few treatment advances over the past several decades. Many drugs that worked against other cancers failed here. That history is exactly why this trial stands out, because it is the first positive phase 3 result for a RAS-targeting drug in this disease.
Bottom Line
In a phase 3 trial of about 500 patients with previously treated metastatic pancreatic cancer, the once-daily pill daraxonrasib nearly doubled median survival compared with chemotherapy, from 6.7 to 13.2 months, while causing fewer side effects. It cut the risk of death by roughly 60 percent and helped patients regardless of RAS mutation status. As the first positive phase 3 trial of a RAS-targeting drug in a disease with almost no progress in decades, this is a landmark step forward, even if it is not yet a cure.
